Compare Kinross Gold Corporation (KGC) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinross Gold Corporation vs Novavax Inc — how do they compare? Kinross Gold Corporation trades at $23.74 (market cap $27.62B), while Novavax Inc trades at $12.75 (market cap $1.82B). The key difference: Kinross Gold Corporation is far larger — about 15.2× Novavax Inc's market cap, and Kinross Gold Corporation pays a 0.69% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kinross Gold Corporation for 53 Days and Novavax Inc for 59 Days on average.
| KGC | NVAX | |
|---|---|---|
Market Cap | $27.62B | $1.82B |
Volume | 6,347,266 | 6,198,505 |
Sector | Basic Materials | Health |
52-Week High | $38.06 | $12.75 |
52-Week Low | $22.47 | $6.22 |
Typical Hold Time | 53 Days | 59 Days |
Enterprise Value | $25.70B | $1.39B |
Dividend Yield | 0.69% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KGC trades at $23.34, up 0.69% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company shows strong fundamentals, with Q2 2026 EPS beating estimates at $0.71 and robust cash flow growth, though recent news highlights production guidance cuts and legal investigations. Valuation ratios remain attractive, with a P/E of 8.87 and EV/EBITDA of 4.59.
The outlook is mixed: strong earnings and cash flow support upside to the $38.80 consensus price target, but risks include cost pressures, production setbacks, and legal scrutiny. Analyst sentiment is bullish with 59% buy ratings, but investors should weigh operational execution against macroeconomic gold price volatility.
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and a strong buy consensus from analysts (73.9% buy ratings). The company reported a net income of $440.3M in 2025, a significant turnaround from prior losses, though 2026 projections show a return to negative margins. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: near-term catalysts include partnership-driven growth and vaccine approvals, but persistent cash burn and projected 2026 losses pose risks. Investor sentiment is buoyed by recent earnings beats and strategic shifts, yet execution on profitability remains critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
